Navigation Links
A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimer's Disease Drug Market
Date:3/6/2008

A Drug's Effect on Cognitive Decline is the Most Important Attribute Influencing Prescribing Decisions, According to a New Report from Decision

Resources

WALTHAM, Mass., March 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug with efficacy superior to that of sales leader memantine would earn up to a 50% patient share in the market to treat moderate-to-severe Alzheimer's disease. The currently available branded versions of memantine are Forest Laboratories' Namenda, Lundbeck's Ebixa and Merz/Grupo Grunenthal's Axura/Akatinol.

The new report entitled Alzheimer's Disease (Moderate to Severe): Incremental Improvements in Efficacy Can Lead to Large Commercial Opportunity finds that a symptomatic therapy with efficacy greater than that of memantine, as measured by the Severe Impairment Battery score at 28 weeks, would earn a patient share of 40-50% in the moderate-to-severe Alzheimer's disease market, according to surveyed neurologists. In addition to replacing memantine in most cases, physicians believe that, if such a therapy were launched, it would threaten a significant percentage of prescriptions of donepezil (Eisai/Pfizer's Aricept and Bracco's Memac) and the memantine/donepezil combination.

The report also finds that a therapy's effect on cognitive decline is the attribute that most influences the prescribing decisions of neurologists in treating moderate-to-severe Alzheimer's disease. Clinical data and interviewed experts indicate that Myriad Genetics' Flurizan, Elan/Wyeth's bapineuzumab, Medivation's Dimebon and Eli Lilly's LY-450139 all have advantages over sales- leading memantine on this attribute.

"Some agents, including Flurizan and bapineuzumab, will be used in combination with existing drugs rather than replacing them," said Nitasha Manchanda, Ph.D., analyst at Decision Resources. "Approximately one-third of the neurologists we surveyed said they will use Flurizan adjunctively and nearly half of the neurologists surveyed will use bapineuzumab as an adjunct to current therapies."

About the Report

Alzheimer's Disease (Moderate to Severe): Incremental Improvements in Efficacy Can Lead to Large Commercial Opportunity is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Radiation and drug combo helps boost efficacy of lung cancer treatment
2. Parents participation in medical decisions linked to self-efficacy
3. Study Shows Cosmetic Surgery on the Rise as Safety and Efficacy of Procedures Increase
4. New strategies with greater antitumorous efficacy
5. Review of probiotic research finds only Bifantis can claim efficacy vs. placebo for IBS symptoms
6. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
7. Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD
8. VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
9. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
10. Study Shows Organons Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
11. Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in property taxes a year. In some states—like New York, New Jersey, Massachusetts, ... contrast, many overseas retirement havens have extremely low property-tax rates, which contributes to ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
Breaking Medicine Technology: